Accession | Title | Series type(s) | Organism(s) | Samples | GDS | Supplementary | Contact | Release date |
---|---|---|---|---|---|---|---|---|
Filter | TSV | Alireza Khodadadi-Jamayran | ||||||
GSE237592 |
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer
|
2 | Alireza Khodadadi-Jamayran | Apr 03, 2024 | ||||
GSE207061 |
Hedgehog signaling affects platelet-derived growth factor signaling mediated alveolar septum formation during postnatal lung development [scRNA-seq]
|
2 | Alireza Khodadadi-Jamayran | Jan 26, 2023 | ||||
GSE176311 |
Exercise-Induced Engagement of the IL-15/IL15Rα axis Promotes Anti Tumor Immunity
|
2 |
|
Alireza Khodadadi-Jamayran | May 11, 2022 | |||
GSE193733 |
Clonal lineage tracing reveals shared origin of conventional and plasmacytoid dendritic cells
|
112 | Alireza Khodadadi-Jamayran | Feb 16, 2022 | ||||
GSE178503 |
EMSY inhibits homologous recombination repair and the interferon response promoting lung cancer immune evasion
|
1 |
|
Alireza Khodadadi-Jamayran | Jan 04, 2022 | |||
GSE156246 |
Ontogeny and Vulnerability of Lapatinib Drug-Tolerant Persisters in HER2-positive Breast Cancer
|
39 |
|
Alireza Khodadadi-Jamayran | Dec 13, 2021 | |||
GSE180964 |
Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC
|
10 |
|
Alireza Khodadadi-Jamayran | Jul 29, 2021 | |||
GSE155340 |
Targeting Piezo1 Unleashes Innate Immunity Against Cancer and Infectious Disease
|
10 |
|
Alireza Khodadadi-Jamayran | Aug 21, 2020 | |||
GSE145328 |
Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma
|
11 |
|
Alireza Khodadadi-Jamayran | Jun 03, 2020 | |||
GSE145905 |
PD-L1 Engagement on T cells Promotes Self-tolerance and Suppression of Neighboring Macrophages and Effector T cells in Cancer
|
17 |
|
Alireza Khodadadi-Jamayran | May 19, 2020 | |||
GSE133604 |
Single-cell transcriptomic profiling of mouse KrasG12DP53-/- (KP) lung tumors in response to tumor cell intrinsic Asf1a knockout (KO), anti-PD-1 or combination treatment (Asf1a KO + anti-PD-1).
|
4 |
|
Alireza Khodadadi-Jamayran | Nov 26, 2019 |